Thirteen years after the GSK China scandal exploded onto the global stage, its lessons remain as urgent as ever for compliance professionals and business leaders. In this podcast series, we revisit the case not simply as corporate history, but as a living cautionary tale about culture, incentives, third parties, investigations, and governance. Each episode explores what went wrong, why it went wrong, and how those failures still echo in today’s compliance and ethics landscape. Join me as we unpack the scandal and draw practical See more +
Thirteen years after the GSK China scandal exploded onto the global stage, its lessons remain as urgent as ever for compliance professionals and business leaders. In this podcast series, we revisit the case not simply as corporate history, but as a living cautionary tale about culture, incentives, third parties, investigations, and governance. Each episode explores what went wrong, why it went wrong, and how those failures still echo in today’s compliance and ethics landscape. Join me as we unpack the scandal and draw practical lessons for building stronger, more resilient organizations.
This episode analyzes the GSK China scandal and its compliance implications, beginning with the 2014 Shanghai trial of private investigators Peter Humphrey and Yu Yingzeng, convicted under a vague 2009 privacy law for illegally purchasing sensitive personal data (IDs, travel, and phone records) using hidden cameras and data brokers, resulting in prison terms and fines. Their arrest overlapped with a GSK-commissioned probe into a sex tape involving China chief Mark Reilly, as China separately convicted GSK in a secret Hunan trial, imposing a record 3 billion RMB (~$491M) fine tied to bribes routed through travel agencies via inflated conference budgets and kickbacks to doctors. Executives gave televised confessions yet received suspended sentences, reflecting a strategy of corporate submission and public exposure over incarceration. The market reaction was muted, but GSK responded by ending payments to doctors and replacing volume-based sales commissions with qualitative metrics, creating a modern compliance blueprint while highlighting ongoing UK Bribery Act and FCPA exposure. Our hosts are Timothy and Fiona.
Key highlights:
• Investigators on Trial
• GSK Secret Verdict
• Executives Sentenced
• Judicial Strategy Explained
• Global Compliance Blueprint
Resources:
• GSK in China: A Game Changer for Compliance on ?Amazon.com?: https://a.co/d/0hOV3GDN
• GSK in China: Anti-Bribery Enforcement Goes Global on ?Amazon.com: https://a.co/d/0adWeJb0 See less -
